Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Apelian, R. G. [1 ]
Boyle, L. [2 ]
Hirman, J. [3 ]
Asher, D. [4 ]
机构：
[1] Huntington Headache & Neurol, Arcadia, CA USA
[2] Lundbeck LLC, Deerfield, IL USA
[3] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[4] Lundbeck LLC, Deerfield, IL USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-181
引用
收藏
页码：151 / 152
页数：2
相关论文
共 50 条
  • [41] Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Schaeffler, Barbara A.
    Biondi, David M.
    Hirman, Joe
    Pederson, Susan
    Allan, Brent
    Smith, Jeff
    CEPHALALGIA, 2020, 40 (03) : 241 - 254
  • [42] Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
    Silberstein, Stephen
    Diamond, Merle
    Hindiyeh, Nada A.
    Biondi, David M.
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Schaeffler, Barbara
    Smith, Jeff
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [43] Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
    Pozo-Rosich, Patricia
    Dodick, David W.
    Ettrup, Anders
    Hirman, Joe
    Cady, Roger
    BMC NEUROLOGY, 2022, 22 (01)
  • [44] Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
    Patricia Pozo-Rosich
    David W. Dodick
    Anders Ettrup
    Joe Hirman
    Roger Cady
    BMC Neurology, 22
  • [45] Eptinezumab Infusion Associated with Meaningful Reductions in Daily Migraine Activity on Day 1 and Over Weeks 1 Through 4 in Patients with Frequent Episodic Migraine: Results of the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial
    Cady, Roger
    Smith, Timothy
    Biondi, David
    Berman, Gary
    Freeman, Marshall
    Hirman, Joe
    Kassel, Eric
    CEPHALALGIA, 2017, 37 : 341 - 342
  • [46] Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study (vol 42, pg 2254, 2020)
    Smith, Timothy R.
    Janelidze, Marina
    Chakhava, George
    Cady, Roger
    Hirman, Joe
    Allan, Brent
    Pederson, Susan
    Smith, Jeff
    Schaeffler, Barbara
    CLINICAL THERAPEUTICS, 2021, 43 (04) : 791 - 791
  • [47] Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, M.
    Diener, H. -C.
    Hirman, J.
    Cady, R.
    Brevig, T.
    Brunner, E.
    Mehta, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
  • [48] Preventive Treatment With Eptinezumab in Patients With a Dual Diagnosis of Chronic Migraine and Medication- Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, Michael J.
    Diener, Hans-Christoph
    Cowan, Robert P.
    Starling, Amaal J.
    Hirman, Joe
    Brevig, Thomas
    Cady, Roger
    NEUROLOGY, 2023, 100 (17)
  • [49] Eptinezumab Reduced Acute Medication Use in Patients With Chronic Migraine and Medication-Overuse Headache: Subgroup Analysis of PROMISE-2
    Marmura, M.
    Diener, H.
    Hirman, J.
    Cady, R.
    Brevig, T.
    Brunner, E.
    Mehta, L.
    HEADACHE, 2020, 60 : 107 - 107
  • [50] Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial
    Smith, Timothy
    Biondi, David
    Berman, Gary
    Freeman, Marshall
    Hirman, Joe
    Kassel, Eric
    NEUROLOGY, 2018, 90
12345